메뉴 건너뛰기




Volumn 174, Issue 6, 2005, Pages 2178-2180

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer

Author keywords

Hypogonadism; Prognosis; Prostatectomy; Prostatic neoplasms; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

EID: 27744467589     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000181818.51977.29     Document Type: Article
Times cited : (108)

References (20)
  • 1
    • 0030913315 scopus 로고    scopus 로고
    • Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
    • Partin, A. W., Rattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J. and Oesterling, J. E.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
    • (1997) JAMA , vol.277 , pp. 1445
    • Partin, A.W.1    Rattan, M.W.2    Subong, E.N.3    Walsh, P.C.4    Wojno, K.J.5    Oesterling, J.E.6
  • 4
    • 0344406150 scopus 로고    scopus 로고
    • Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
    • Massengill, J. C., Sun, L., Moul, J. W., Wu, H., McLeod, D. G., Amling, C. et al: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol, 169: 1670, 2003
    • (2003) J Urol , vol.169 , pp. 1670
    • Massengill, J.C.1    Sun, L.2    Moul, J.W.3    Wu, H.4    McLeod, D.G.5    Amling, C.6
  • 5
    • 0033950926 scopus 로고    scopus 로고
    • Is low serum free testosterone a marker for high-grade prostate cancer?
    • Hoffman, M. A., DeWolf, W. C. and Morgentaler, A.: Is low serum free testosterone a marker for high-grade prostate cancer? J Urol, 163: 824, 2000
    • (2000) J Urol , vol.163 , pp. 824
    • Hoffman, M.A.1    Dewolf, W.C.2    Morgentaler, A.3
  • 6
    • 0036224481 scopus 로고    scopus 로고
    • The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis
    • Chen, S. S., Chen, K. K., Lin, A. T., Chang, Y. H., Wu, H. H. and Chang, L. S.: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int, 89: 710, 2002
    • (2002) BJU Int , vol.89 , pp. 710
    • Chen, S.S.1    Chen, K.K.2    Lin, A.T.3    Chang, Y.H.4    Wu, H.H.5    Chang, L.S.6
  • 7
    • 0034767957 scopus 로고    scopus 로고
    • Cancer burden in the year 2000. The global picture
    • Parkin, D. M., Bray, F. I. and Devesa, S. S.: Cancer burden in the year 2000. The global picture. Eur J Cancer, suppl., 37: S4, 2001
    • (2001) Eur J Cancer , vol.37 , Issue.SUPPL.
    • Parkin, D.M.1    Bray, F.I.2    Devesa, S.S.3
  • 9
    • 0037388135 scopus 로고    scopus 로고
    • Recent trends in prostate cancer incidence and mortality in southeast England
    • Evans, H. S. and Moller, H.: Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol, 43: 337, 2003
    • (2003) Eur Urol , vol.43 , pp. 337
    • Evans, H.S.1    Moller, H.2
  • 10
    • 8444233301 scopus 로고    scopus 로고
    • Clinical consequences of screening for prostate cancer: 15 Years follow-up of a randomised controlled trial in Sweden
    • Sandblom, G., Varenhorst, E., Lofman, O., Rosell, J. and Carlsson, P.: Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol, 46: 717, 2004
    • (2004) Eur Urol , vol.46 , pp. 717
    • Sandblom, G.1    Varenhorst, E.2    Lofman, O.3    Rosell, J.4    Carlsson, P.5
  • 11
    • 0036845766 scopus 로고    scopus 로고
    • Improved prostate cancer-specific survival and other disease parameters: Impact of prostate-specific antigen testing
    • Paquette, E. L., Sun, L., Paquette, L. R., Connelly, R., Mcleod, D. G. and Moul, J. W.: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology, 60: 756, 2002
    • (2002) Urology , vol.60 , pp. 756
    • Paquette, E.L.1    Sun, L.2    Paquette, L.R.3    Connelly, R.4    Mcleod, D.G.5    Moul, J.W.6
  • 12
    • 0028183087 scopus 로고
    • Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma
    • Iversen, P., Rasmussen, F. and Christensen, I. J.: Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl, 157: 41, 1994
    • (1994) Scand J Urol Nephrol Suppl , vol.157 , pp. 41
    • Iversen, P.1    Rasmussen, F.2    Christensen, I.J.3
  • 14
    • 85136393621 scopus 로고    scopus 로고
    • Occult prostate cancer in men with low serum testosterone levels
    • Morgentaler, A., Bruning, C. O., 3rd and DeWolf, W. C.: Occult prostate cancer in men with low serum testosterone levels. JAMA, 276: 1904, 1996
    • (1996) JAMA , vol.1904 , pp. 276
    • Morgentaler, A.1    Bruning III, C.O.2    Dewolf, W.C.3
  • 15
    • 0021336526 scopus 로고
    • Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival
    • Harper, M. E., Pierrepoint, C. G. and Griffiths, K.: Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol, 20: 477, 1984
    • (1984) Eur J Cancer Clin Oncol , vol.20 , pp. 477
    • Harper, M.E.1    Pierrepoint, C.G.2    Griffiths, K.3
  • 16
    • 0014296416 scopus 로고
    • Plasma testosterone levels in patients with prostatic carcinoma before and after treatment
    • Young, H. H., 2nd and Kent, J. R.: Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol, 99: 788, 1968
    • (1968) J Urol , vol.99 , pp. 788
    • Young II, H.1    Kent, J.R.2
  • 17
    • 0015222344 scopus 로고
    • Effect of hormonal therapy on plasma testosterone levels in prostatic cancer
    • Robinson, M. R. and Thomas, B. S.: Effect of hormonal therapy on plasma testosterone levels in prostatic cancer. Br Med J, 4: 391, 1971
    • (1971) Br Med J , vol.4 , pp. 391
    • Robinson, M.R.1    Thomas, B.S.2
  • 18
    • 0026021087 scopus 로고
    • Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group
    • Chodak, G. W., Vogelzang, N. J., Caplan, R. J., Soloway, M. and Smith, J. A.: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA, 265: 618, 1991
    • (1991) JAMA , vol.265 , pp. 618
    • Chodak, G.W.1    Vogelzang, N.J.2    Caplan, R.J.3    Soloway, M.4    Smith, J.A.5
  • 19
    • 0023573211 scopus 로고
    • Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade
    • Harper, M. E., Wilson, D. W., Jensen, H. M., Pierrepoint, C. G. and Griffiths, K.: Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade. J Steroid Biochem, 27: 521, 1987
    • (1987) J Steroid Biochem , vol.27 , pp. 521
    • Harper, M.E.1    Wilson, D.W.2    Jensen, H.M.3    Pierrepoint, C.G.4    Griffiths, K.5
  • 20
    • 0030891205 scopus 로고    scopus 로고
    • Serum testosterone-a significant determinant of metastatic relapse for irradiated localized prostate cancer
    • Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Serum testosterone-a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology, 40: 327, 1997
    • (1997) Urology , vol.40 , pp. 327
    • Zagars, G.K.1    Pollack, A.2    Von Eschenbach, A.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.